3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow rFIXFc: new trials by email Literature Review of rFIXFc trials Research Report on rFIXFc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B rFIXFc - Hemophilia B | Phase 3 | Completed | Bioverativ, a Sanofi company | 33 | 2014-11-13 | 2022-03-25 |
| Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B rFIXFc, FIX - Hemophilia B | Phase 3 | Completed | Bioverativ Therapeutics Inc. | 30 | 2012-06-01 | 2020-12-19 |
| Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B rFIXFc - Severe Hemophilia B | Phase 3 | Completed | Bioverativ Therapeutics Inc. | 120 | 2011-12-08 | 2020-12-19 |
Hemophilia B (3)
Bioverativ Therapeutics Inc. (2) · Bioverativ, a Sanofi company (1)
Australia (3) · Ireland (3) · Netherlands (3) · United Kingdom (3) · United States (3) · France (2) · Italy (2) · Poland (2) · South Africa (2) · Sweden (2) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Denmark (1)
PMID 36848635, PMID 28159192, PMID 30656283, PMID 34242387, PMID 37283819, PMID 38922990